Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

ABSTRACT:

Background

Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient.

Methods

In this Toca 511 ascending-dose phase I trial (NCT01470794), HGG patients who recurred after standard of care underwent surgical resection and received Toca 511 injected into th

SUBMITTER: Cloughesy TF 

PROVIDER: S-EPMC6120351 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature